Journal of International Oncology››2016,Vol. 43››Issue (3): 210-212.doi:10.3760/cma.j.issn.1673422X.2016.03.013

Previous ArticlesNext Articles

Adjuvant endocrine therapy for breast cancer

Liu Xiaoling, Li Wenhui, Chang Li, Xia Yaoxiong

  1. Department of Radiation Oncology, Yunnan Tumor Hospital, Third Affiliated Hospital of Kunming Medical University, Kunming 650118, China
  • Online:2016-03-08Published:2016-02-03
  • Contact:Li Wenhui, Email: wenhuili64@aliyun.com E-mail:wenhuili64@aliyun.com
  • Supported by:

    Health Science and Technology Planning Project of Yunnan Province(2012WS0039)

Abstract:Endocrinotherapy is an important treatment approach for patients with hormone receptor-positive breast cancer. Tamoxifen, anastrozole and ovarian function inhibitors are the most common drugs in breast cancer endocrinotherapy. However, the choices of endocrinotherapy drugs are different on the basis of the differences in disease stages and menopausal status. Endocrinotherapy has been proved to have good effects, meanwhile, also been shown to can produce drug resistance, mTOR inhibitors, CDK4/6 inhibitors and fibroblast growth factor receptor inhibitors will bring new hope for patients with drug resistance to endocrinotherapy.

Key words:Breast neoplasms,Estrogens